JANX News and Press, Janux Therapeutics Inc. From 10/28/25

2025-10-28 10:11:44 ET More on Janux Therapeutics Janux: A High-Risk/High-Reward Bet On Oncology And Autoimmune Therapies Backed By $1B In Cash Janux is a new Buy at Truist ahead of catalyst rich H2 Piper Sandler initiates coverage of oncology companies Seeki...

2025-09-10 14:43:42 ET More on Janux Therapeutics Janux: A High-Risk/High-Reward Bet On Oncology And Autoimmune Therapies Backed By $1B In Cash Piper Sandler initiates coverage of oncology companies Seeking Alpha’s Quant Rating on Janux Therapeutics Hi...

2025-08-07 17:41:36 ET More on Janux Therapeutics Janux: A High-Risk/High-Reward Bet On Oncology And Autoimmune Therapies Backed By $1B In Cash SA Asks: Which oncology companies are attractive M&A targets? Seeking Alpha’s Quant Rating on Janux Therapeutics...

R&D Day highlighted TRACTr, TRACIr, and ARM pipeline progress and best-in-class potential of novel bispecific ARM platform for autoimmune diseases Enrollment ongoing for JANX007 and JANX008 Updates on JANX007 and JANX008 expected in the second half of 2025 First patien...

Sera Prognostics Inc. (SERA) is expected to report $-0.21 for Q2 2025 D/B/A Compass Diversified Holdings Shares of Beneficial Interest (CODI) is expected to report $0.51 for Q2 2025 Context Therapeutics Inc. (CNTX) is expected to report $-0.06 for Q2 2025 Genco Shipping & Trading ...

Janux Therapeutics Inc. (JANX) is expected to report $-0.48 for Q2 2025

First patient dosed in the lead collaboration program triggers a $10 million milestone payment to Janux Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary tech...

2025-07-31 00:01:40 ET Thesis Janux Therapeutics ( JANX )’s know-how and scientific development have raised a lot of interest among investors, as well as numerous buy-out rumors. Although I would not discard the possibility of a buyout, I want to center my analysis on the...

PSMA-TRACIr designed to be combined with potentially best-in-treatment asset, JANX007, and provide CD28 co-stimulation to further differentiate depth and durability of patient responses. TROP2-TRACTr adds first-in-class and best-in-class opportunity targeting multiple solid tumors with pr...

Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today an...